News
You’re invited to a patient seminar – Wellington
INVITATION Patient Seminar: CAR T-Cell Therapy: a New Frontier in Blood Cancer Treatment Presented by Dr Rob Weinkove on 8 March, 5.30-7pm at...
You’re invited to a patient seminar – Auckland
INVITATION Patient Seminar: What's New in Myeloma Treatment: a New Zealand Perspective with...
Multinational Clinical Study
Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory...
Tell us how we can help
We're keen to know how Myeloma New Zealand can help you. What you'd like to hear about on the website? What support you feel would be useful? We'd...
FDA Grants BCMA CAR T-Cell Therapy Breakthrough Designation in Myeloma
The FDA has granted bb2121 a breakthrough therapy designation for previously treated patients with relapsed/refractory multiple myeloma, according...
You’re invited to a patient seminar
INVITATION Patient Seminar:  Improving Survival in Multiple Myeloma Dr. Henry Chan from North Shore Hospital will be speaking at our patient seminar...
Daratumumab approved for use on NHS in Scotland
Patients in Scotland will now be able to access the new myeloma treatment, daratumumab (Darzalex®) on the NHS, after the Scottish Medicines...
Article of the Week: Delineation of the timing of second-line therapy post–autologous stem cell transplant in patients with AL amyloidosis
For this week's Article of the Week, we look at an article that describes a review of patient data from the Mayo Clinic. The study sought to...
Article of the week: Genetic changes associated with the evolution of Monoclonal Gammopathy of Unknown Significance (MGUS)
For this week's Article of the Week we have chosen a review article published in the British Journal of Haematology co-authored by MSAG member Dr...
Article of the week: Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease
For this week's Article of the Week we have chosen an article which is particularly relevant to the results of the recent VCAT study which is...
Article of the week: The use of sclerostin to increase bone mass and reduce the incidence of fractures in multiple myeloma
For this week's Article of the Week relates to a presentation made by Petere Croucher on the osteocyte-specific protein sclerostin at the most...
Article of the week: Letters to Blood – Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
GarcÃa-Guerrero et al described their laboratory study where myeloma cells from 12 patients were treated with titrated doses of panobinostat (0, 10...